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E-mail address: bkay@uic.eduWith the sequencing of an eukaryotic genome, it is possible to inventory the predicted proteome for
proteins that carry one or more Src Homology 3 (SH3) domains. Due to the current ease of cloning
and gene synthesis, these short domains can be readily overexpressed and manipulated for the pur-
pose of characterizing their speciﬁcity and afﬁnity for peptide ligands, as well as solving the three-
dimensional structures of the domains. This information can be used to predict and conﬁrm their
cellular interacting partners, in the effort to understand the function of a eukaryotic protein by
focusing on its SH3 domain. Finally, capitalizing on our mature understanding about protein–
protein interacting modules, like the SH3 domain, it is possible to use directed evolution to enhance
or change the speciﬁcity and afﬁnity of an SH3 domain for the purpose of creating reagents to be
used in biochemical puriﬁcation or cell perturbation studies.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Overview conformational and sequence variability created by these two sur-Our understanding of Src Homology 3 (SH3) domains has come
long way since the early 1988, when they were identiﬁed as a 60
amino acid segments shared among diverse signaling and cytoskel-
etal proteins of eukaryotes [1–3]. Since then, their three-dimen-
sional structure has been determined [4,5], and it was recognized
that they, along with other protein interaction modules [6], bind
short proline-rich peptide segments within proteins [7,8]. Since
these seminal discoveries, the scientiﬁc community has busily cat-
aloged SH3 domains in the various genomes [9] of eukaryotes, and
deﬁned their potential cellular, interacting partners, either directly
through biochemical characterization [10] or indirectly by deﬁning
their speciﬁcity with combinatorial peptide libraries [11–14].
The three-dimensional structure of SH3 domains is highly
conserved, even though the amino acid similarity of any two SH3
domains is typically 25%. Like many other protein interaction
modules, the N-terminus and C-terminus of this 60 amino acid long
domain are next to each other, on the side opposite to its binding
surface [4]. The domain is composed of two perpendicular, three-
stranded anti-parallel beta sheets, with a shallow groove formed
by the RT and the n-Src loops [15]. It has been proposed that thechemical Societies. Published by Eface loops accounts for the ligand speciﬁcity of SH3 domains [16].
With the availability of complete genome sequences, one can
now today use a variety of techniques to characterize and compare
the speciﬁcity of SH3 domains fromany organism (Fig. 1). For exam-
ple, one can predict the ‘SH3 domain interactome’ (i.e., the interac-
tion of SH3 domains with proteins within a certain cell type) by
screening large arrays of synthetic peptides, corresponding to
proteins predicted from genomics sequences [17], afﬁnity selection
of phage-displayed SH3 domains [18] with individual peptide
sequences, or through large-scale yeast two-hybrid screening [19].
Additionally, with the implementation of high-throughput molecu-
lar biology techniques and liquid handling robotics, it is straightfor-
ward to amplify their 180 nucleotide long coding regions from
mRNA or genomic DNA by the polymerase chain reaction (PCR);
alternatively, due the decreased cost of oligonucleotides, one can
order their coding regions synthesized. Thus, large sets of SH3 do-
mains can be constructed, and probedwith various labeled proteins
or peptides [20–22]. In the future, it may be possible to use solid-
phase peptide synthesis and chemical ligation to generate the SH3
domain domains chemically [23], both in large number and in an
economical fashion, and deﬁne their speciﬁcity accordingly. In par-
allel to experimental effort, computational approaches are also
being pursued for predicting the SH3 domain interactome of organ-
isms [19,24,25].lsevier B.V. All rights reserved.
Fig. 1. The current workﬂow for characterizing SH3 domains. Through bioinformat-
ics, an inventory of SH3 domains can be created from a genome’s sequence, and
coding regions for domains of interest can be recovered through cloning or by gene
synthesis. The domains can then be overexpressed and puriﬁed from E. coli, and used
to screen peptide arrays or phage-displayed combinatorial peptide libraries. Once
peptide ligands for an SH3 domain have been identiﬁed, the cellular interacting
partner can be predicted. Alternatively, the SH3 domain coding region can be used in
yeast two-hybrid screening experiments or the domain can be used to pull-down
interacting proteins from cell/tissue lysates. The three-dimensional (3D) structure
can be deduced by X-ray diffraction or nuclear magnetic resonance, and computa-
tional techniques can be applied to predict their peptide ligands. It is also fruitful to
used directed evolution methods to change the speciﬁcity and/or afﬁnity of a
particular SH3 domain for the purpose of generating a novel recombinant afﬁnity
reagent or tool for cellular perturbation studies.
B.K. Kay / FEBS Letters 586 (2012) 2606–2608 2607Fortunately, most SH3 domains are well expressed in the cytosol
of Escherichia coli, and remain stably folded after puriﬁcation. The
domains are thermal stable, with melting temperature in the range
of 60–75 C [26]. The ability to express the small, stable domain eas-
ily in E. coli has prompted many lines of investigation (Fig. 1). First,
their afﬁnity, which is typically low micromolar to mid-nanomolar
for peptide ligands and cellular interacting proteins, respectively,
can been improved at least 40-fold by directed evolution [27].
Second, by randomizing the residues in the RT and n-Src loops, it
has been possible to generate new SH3 domainswith novel speciﬁc-
ities [28–30]. Such engineered SH3 domains offer interesting prom-
ise as a new class of recombinant afﬁnity reagents [31,32] that can
be used in proteomic and cellular perturbation studies. Third, SH3
domains can be combined with recombinant antibody fragments
to generate reagents that bind avidly to cellular targets [33].
In conclusion, through advancements in molecular biology,
genomic sequencing, and bioinformatics, it is now straight-forward
for any laboratory to characterize from one to hundreds of SH3
domains at a time, and predict genome-wide protein–protein
interactions in any organism. Furthermore, they can utilized in bio-
technological applications for protein engineering and synthetic
biology. SH3 domains have truly ‘come of age’!
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